Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2021

01-02-2021 | Breast Cancer | Letter to the Editor

Letter to the Editor regarding the publication titled “Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough?”

Authors: Rosa Di Micco, Jean-Marc Classe, Toralf Reimer, EUBREAST founding members

Published in: Breast Cancer Research and Treatment | Issue 1/2021

Login to get access

Excerpt

To the editor, …
Literature
1.
Rosenberger LH, Ren Y, Thomas SM, Greenup RA, Fayanju OM, Hwang ES et al (2020) Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough? Breast Cancer Res Treat 179(3):661–670CrossRef
2.
Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N (2002) Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347(8):567–575CrossRef
3.
Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR et al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 318(10):918–926CrossRef
Metadata
Title
Letter to the Editor regarding the publication titled “Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough?”
Authors
Rosa Di Micco
Jean-Marc Classe
Toralf Reimer
EUBREAST founding members
Publication date
01-02-2021
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2021
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-06064-9

Other articles of this Issue 1/2021

Breast Cancer Research and Treatment 1/2021 Go to the issue

Epidemiology

Drug use disorder and risk of incident and fatal breast cancer: a nationwide epidemiological study

Epidemiology

The relationship between the predicted risk of death and psychosocial functioning among women with early-stage breast cancer

Preclinical study

HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells

Epidemiology

Association of relative dose intensity with BMI and pathologic complete response in patients treated with neoadjuvant chemotherapy for breast cancer

Preclinical study

HER2 fluorescent in situ hybridization signal degradation: a 10-year retrospective study

Brief Report

Double heterozygosity for TP53 and BRCA1 mutations: clinical implications in populations with founder mutations
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits